These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3680816)

  • 1. Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing.
    Milavetz G; Vaughan LM; Weinberger MM; Harris JB; Mullenix TA
    J Allergy Clin Immunol; 1987 Nov; 80(5):723-9. PubMed ID: 3680816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity.
    Hendeles L; Weinberger M; Milavetz G; Hill M; Vaughan L
    Chest; 1985 Jun; 87(6):758-65. PubMed ID: 3996063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets.
    Arkinstall WW; Hopkinson M; Rivington RN; Calcutt L; Aitken T; Stewart JH
    J Allergy Clin Immunol; 1988 Aug; 82(2):155-64. PubMed ID: 3273483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
    Weinberger MM
    Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theophylline product and dosing interval selection for chronic asthma.
    Hendeles L; Weinberger M
    J Allergy Clin Immunol; 1985 Aug; 76(2 Pt 2):285-91. PubMed ID: 4019956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of a slow-release theophylline product.
    Hendeles L; Weinberger M
    J Allergy Clin Immunol; 1986 Oct; 78(4 Pt 2):743-51. PubMed ID: 3534055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the pharmacodynamics and pharmacokinetics of theophylline.
    Hendeles L; Massanari M; Weinberger M
    Chest; 1985 Aug; 88(2 Suppl):103S-111S. PubMed ID: 3893922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation of product formulation to absorption of oral theophylline.
    Weinberger M; Hendeles L; Bighley L
    N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma.
    Weinberger M; Hendeles L; Wong L
    J Pediatr; 1981 Jul; 99(1):145-52. PubMed ID: 7252652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absorption characteristics of six sustained-release theophylline preparations.
    Sommers DK; van Wyk M; Meyer EC; Snyman JR; Moncrieff J
    S Afr Med J; 1992 Jan; 81(1):20-2. PubMed ID: 1729729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients.
    Fradette M; Babich M; Friesen EG; Archibald JS; Babul N
    Clin Ther; 1994; 16(2):160-8. PubMed ID: 8062311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption characteristics of once-a-day slow-release theophylline preparation in children with asthma.
    Pedersen S; Steffensen G
    J Pediatr; 1987 Jun; 110(6):953-9. PubMed ID: 3585612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur).
    Oosterhuis B; Brannan MD; Groen H; Peeters PA; Hempenius J; Radwanski E; Nomeir AA; Affrime MB; Jonkman JH
    Ann Allergy Asthma Immunol; 1995 Aug; 75(2):157-61. PubMed ID: 7648380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
    González MA; Straughan AB
    Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption.
    Karim A; Burns T; Janky D; Hurwitz A
    Clin Pharmacol Ther; 1985 Dec; 38(6):642-7. PubMed ID: 4064466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose dependency for absorption and elimination rates of theophylline. Implications for studies of bioavailability.
    Milavetz G; Weinberger M; Vaughan L
    Pharmacotherapy; 1984; 4(4):216-20. PubMed ID: 6483638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of food on steady state serum concentrations of theophylline from two controlled-release preparations.
    Lefebvre RA; Belpaire FM; Bogaert MG
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):375-9. PubMed ID: 3220610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theophylline levels and clinical response in asthmatic adults receiving long-term Uniphyl.
    Petty TL; Rollins DL
    Am J Med; 1985 Dec; 79(6A):73-6. PubMed ID: 2867679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.